Literature DB >> 31079969

Different inflammatory profile in young and elderly STEMI patients undergoing primary percutaneous coronary intervention (PPCI): Its influence on no-reflow and mortality.

Serena Del Turco1, Giuseppina Basta2, Alberto Ranieri De Caterina3, Silverio Sbrana2, Umberto Paradossi3, Alessandro Taddei3, Giuseppe Trianni3, Marcello Ravani3, Cataldo Palmieri3, Sergio Berti3, Annamaria Mazzone3.   

Abstract

BACKGROUND: Coronary no-reflow phenomenon in ST-segment elevation myocardial infarction (STEMI) is associated with a poor clinical prognosis. Although its pathophysiology is not fully elucidated, a deregulated systemic inflammatory response plays an important role. Specifically, the relationship between age-associated differences in inflammatory markers and either no-reflow or mortality in STEMI patients undergoing primary percutaneous coronary intervention (pPCI) has never been investigated. METHODS AND
RESULTS: We retrospectively enrolled 625 consecutive STEMI patients undergoing pPCI for whom a complete laboratory inflammatory pattern was available. Routinely blood measured laboratory parameters were collected at the moment of admission. No reflow was defined as Thrombolysis in Myocardial Infarction (TIMI) flow-grade lower than 3. The population was divided into two groups using a cut-off centered at 65 years. Compared to younger patients, elderly patients had higher mean values of fibrinogen, brain natriuretic peptide (BNP), leukocytes, neutrophil-to-lymphocyte ratio (NLR), C reactive protein/albumin ratio (CAR). Conversely, lymphocyte count and albumin levels were higher in young patients. In elderly patients, the values of NLR, CAR as well as leukocytes, fibrinogen and neutrophils were associated with no-reflow, while in young patients only BNP value was associated. At multivariate Cox regression analysis, only BNP and NLR resulted as independent predictors of all-cause mortality in the whole population and in elderly patients.
CONCLUSIONS: Elderly STEMI patients on admission had a higher acute pro-inflammatory profile than young patients, associated to coronary no-reflow and mortality outcome. These results suggest that a different therapeutic approach between elderly and young STEMI patients should be agreed.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Elderly patients; Inflammation; No-reflow phenomenon; ST-elevation myocardial infarction

Mesh:

Substances:

Year:  2019        PMID: 31079969     DOI: 10.1016/j.ijcard.2019.05.002

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Nomogram for the Prediction of Intrahospital Mortality Risk of Patients with ST-Segment Elevation Myocardial Infarction Complicated with Hyperuricemia: A Multicenter Retrospective Study.

Authors:  Zhixun Bai; Yi Ma; Zhiyun Shi; Ting Li; Shan Hu; Bei Shi
Journal:  Ther Clin Risk Manag       Date:  2021-08-21       Impact factor: 2.423

2.  Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention.

Authors:  Shu-Min Chang; Yan-Tan Yu; Bo Luan; Ai-Jie Hou; Yong Wang
Journal:  J Interv Cardiol       Date:  2022-04-15       Impact factor: 1.776

3.  No-reflow phenomenon in acute myocardial infarction: Relieve pressure from the procedure and focus attention to the patient.

Authors:  Andrea Buono; Tommaso Gori
Journal:  Int J Cardiol Heart Vasc       Date:  2019-08-30

4.  C-reactive Protein/Albumin Ratio and Acute Kidney Injury after Radical Cystectomy among Elderly Patients: A Propensity Score-Matched Analysis.

Authors:  Jihion Yu; Jun-Young Park; Seungsoo Ha; Jai-Hyun Hwang; Young-Kug Kim
Journal:  Dis Markers       Date:  2020-10-27       Impact factor: 3.434

5.  Association of circulating B-type natriuretic peptide with osteoporosis in a Chinese type 2 diabetic population.

Authors:  Pan Chen; Pijun Yan; Qin Wan; Zhihong Zhang; Yong Xu; Ying Miao; Jun Yang
Journal:  BMC Musculoskelet Disord       Date:  2021-03-10       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.